Computer Science · Artificial Intelligence
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267–270
Wenhua Zhang, Robert M. Friedl
See on the mapAbstract
The known neuroprotective effects of minocycline and creatine in animal models of amyotrophic lateral sclerosis (ALS) led us to examine whether the combination of these agents would result in increased neuroprotection. As previously reported, we confirmed in ALS mice that either minocycline or creatine treatment results in improvement in motor performance and extended survival. We report that combination of minocycline and creatine resulted in additive neuroprotection, suggesting this to be a novel potential strategy for the treatment of ALS. To our knowledge, this is the first report demonstrating additive neuroprotection of a combinatorial approach in a mouse model of ALS. Adding relevancy to our findings, minocycline and creatine, are relatively safe, cross the blood–brain barrier, and are currently available for human evaluation. Ann Neurol 2003;53:267–270 Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative disease characterized by progressive motor weakness resulting from selective motor neuron cell death. 1 Mortality is seen on the average 4 years after disease onset. Proven therapeutic options are limited to riluzole, which extends survival by an average of 3 months. 1 It is therefore of utmost importance to develop novel and more effective therapeutics for this universally fatal devastating disease. Because of the multifactorial downstream pathogenic pathways activated in ALS, improving therapeutic efficacy will depend on implementing a strategy addressing multiple components of the pathogenesis. Combinatorial therapeutics have been implemented with varying degrees of